FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997201694> ?p ?o ?g. }

• W1997201694 endingPage "431" @default.
• W1997201694 startingPage "423" @default.
• W1997201694 abstract "Abstract Anti‐angiogenesis is a promising strategy for cancer therapy currently evaluated in clinical trials. The aim of the study was to investigate the effects of an antiangiogenic combination therapy inhibiting α v ‐integrins by a c(yclic)RGD‐peptide (EMD270179) and blocking VEGFR‐2 by SU5416 on tumor angiogenesis and progression in vivo . Experiments were performed in dorsal skinfold chamber preparations of Syrian golden hamster s (60 ± 5 g) bearing A‐Mel‐3 tumors. From day 3–10 after tumor‐cell implantation, animals ( n = 6 per group) were treated by monotherapies using the cRGD‐peptide (114 mg/kg/day; i.p.), the VEGFR‐2 antagonist (6 mg/kg/day; i.p.) or by the combination of both monotherapies. A control group received only the solvent DMSO. Using intravital microscopy parameters of intratumoral microcirculation were analyzed on day 5, 7 and 10. In separate experiments subcutaneous tumor growth and metastasis formation was evaluated starting therapy on day 0. Functional vessel density was significantly reduced by the combination therapy compared to that by all other groups on day 10. Although intratumoral red blood cell velocity and vessel diameters were less affected, blood flow in vessel segments and the microcirculatory perfusion index were lower after combined therapy compared to controls. In addition, we observed a significantly stronger inhibition of subcutaneous tumor growth and metastasis formation using the combination therapy. These data clearly support the concept of antiangiogenic combination therapy and demonstrate that it may especially be effective when scheduled as an early or prophylactic treatment regimen, thus avoiding angiogenesis‐dependent tumor and metastasis initiation or tumor recurrence. © 2006 Wiley‐Liss, Inc." @default.
• W1997201694 created "2016-06-24" @default.
• W1997201694 creator A5015864380 @default.
• W1997201694 creator A5025130428 @default.
• W1997201694 creator A5025651702 @default.
• W1997201694 creator A5027867640 @default.
• W1997201694 creator A5076234765 @default.
• W1997201694 creator A5086608438 @default.
• W1997201694 date "2006-04-27" @default.
• W1997201694 modified "2023-10-18" @default.
• W1997201694 title "Antiangiogenic combination tumor therapy blocking α_v‐integrins and VEGF‐receptor‐2 increases therapeutic effects <i>in vivo</i>" @default.
• W1997201694 cites W1533067566 @default.
• W1997201694 cites W1972870829 @default.
• W1997201694 cites W1979887297 @default.
• W1997201694 cites W2001753204 @default.
• W1997201694 cites W2006202974 @default.
• W1997201694 cites W2014144825 @default.
• W1997201694 cites W2014409756 @default.
• W1997201694 cites W2015809080 @default.
• W1997201694 cites W2021528243 @default.
• W1997201694 cites W2023371975 @default.
• W1997201694 cites W2028972436 @default.
• W1997201694 cites W2029773366 @default.
• W1997201694 cites W2029883816 @default.
• W1997201694 cites W2039317622 @default.
• W1997201694 cites W2040283898 @default.
• W1997201694 cites W2043410848 @default.
• W1997201694 cites W2048640269 @default.
• W1997201694 cites W2052582923 @default.
• W1997201694 cites W2059721098 @default.
• W1997201694 cites W2064360454 @default.
• W1997201694 cites W2067754613 @default.
• W1997201694 cites W2112940666 @default.
• W1997201694 cites W2114055410 @default.
• W1997201694 cites W2120018694 @default.
• W1997201694 cites W2120921677 @default.
• W1997201694 cites W2137841367 @default.
• W1997201694 cites W2153839353 @default.
• W1997201694 cites W2157769714 @default.
• W1997201694 cites W2159789252 @default.
• W1997201694 cites W2160621818 @default.
• W1997201694 cites W2163124389 @default.
• W1997201694 cites W2169102763 @default.
• W1997201694 cites W2169965478 @default.
• W1997201694 cites W2467950813 @default.
• W1997201694 cites W4232427147 @default.
• W1997201694 doi "https://doi.org/10.1002/ijc.21838" @default.
• W1997201694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16477628" @default.
• W1997201694 hasPublicationYear "2006" @default.
• W1997201694 type Work @default.
• W1997201694 sameAs 1997201694 @default.
• W1997201694 citedByCount "38" @default.
• W1997201694 countsByYear W19972016942012 @default.
• W1997201694 countsByYear W19972016942014 @default.
• W1997201694 countsByYear W19972016942016 @default.
• W1997201694 countsByYear W19972016942018 @default.
• W1997201694 countsByYear W19972016942019 @default.
• W1997201694 crossrefType "journal-article" @default.
• W1997201694 hasAuthorship W1997201694A5015864380 @default.
• W1997201694 hasAuthorship W1997201694A5025130428 @default.
• W1997201694 hasAuthorship W1997201694A5025651702 @default.
• W1997201694 hasAuthorship W1997201694A5027867640 @default.
• W1997201694 hasAuthorship W1997201694A5076234765 @default.
• W1997201694 hasAuthorship W1997201694A5086608438 @default.
• W1997201694 hasBestOaLocation W19972016941 @default.
• W1997201694 hasConcept C121608353 @default.
• W1997201694 hasConcept C126322002 @default.
• W1997201694 hasConcept C12722491 @default.
• W1997201694 hasConcept C142724271 @default.
• W1997201694 hasConcept C150903083 @default.
• W1997201694 hasConcept C207001950 @default.
• W1997201694 hasConcept C2776999253 @default.
• W1997201694 hasConcept C2778271429 @default.
• W1997201694 hasConcept C2779013556 @default.
• W1997201694 hasConcept C2780394083 @default.
• W1997201694 hasConcept C502942594 @default.
• W1997201694 hasConcept C71924100 @default.
• W1997201694 hasConcept C86803240 @default.
• W1997201694 hasConcept C98274493 @default.
• W1997201694 hasConceptScore W1997201694C121608353 @default.
• W1997201694 hasConceptScore W1997201694C126322002 @default.
• W1997201694 hasConceptScore W1997201694C12722491 @default.
• W1997201694 hasConceptScore W1997201694C142724271 @default.
• W1997201694 hasConceptScore W1997201694C150903083 @default.
• W1997201694 hasConceptScore W1997201694C207001950 @default.
• W1997201694 hasConceptScore W1997201694C2776999253 @default.
• W1997201694 hasConceptScore W1997201694C2778271429 @default.
• W1997201694 hasConceptScore W1997201694C2779013556 @default.
• W1997201694 hasConceptScore W1997201694C2780394083 @default.
• W1997201694 hasConceptScore W1997201694C502942594 @default.
• W1997201694 hasConceptScore W1997201694C71924100 @default.
• W1997201694 hasConceptScore W1997201694C86803240 @default.
• W1997201694 hasConceptScore W1997201694C98274493 @default.
• W1997201694 hasIssue "2" @default.
• W1997201694 hasLocation W19972016941 @default.
• W1997201694 hasLocation W19972016942 @default.
• W1997201694 hasOpenAccess W1997201694 @default.
• W1997201694 hasPrimaryLocation W19972016941 @default.

• next